Residency · Residency · Rheumatology

Fibromyalgia and Central Sensitization

Introduction

Fibromyalgia is a chronic widespread pain syndrome characterized by central sensitization, fatigue, sleep disturbance, and cognitive dysfunction. It affects approximately 2 to 4 percent of the general population, with a female-to-male ratio of 2-3:1, although this ratio has narrowed with the adoption of updated diagnostic criteria that no longer rely on tender point examination. Fibromyalgia is among the most common reasons for referral to rheumatology practices, and its recognition as a legitimate neurobiological disorder has transformed clinical approaches over the past two decades. Importantly, fibromyalgia is not a diagnosis of exclusion. It can be positively diagnosed using validated criteria and can coexist with other rheumatic diseases, including rheumatoid arthritis, systemic lupus erythematosus, and osteoarthritis. The 2016 ACR diagnostic criteria replaced the original 1990 tender point criteria, reflecting an improved understanding of the condition's pathophysiology and clinical heterogeneity.

Pathophysiology

Central Sensitization

The core mechanism underlying fibromyalgia is augmented central pain processing coupled with reduced descending inhibitory modulation. In the spinal cord dorsal horn, there is hyperexcitability of second-order neurons driven by increased release of excitatory neurotransmitters, including substance P and glutamate. Cerebrospinal fluid levels of substance P are elevated two- to three-fold above normal in fibromyalgia patients, providing direct biochemical evidence of central sensitization. Simultaneously, the descending pain inhibitory pathways that originate in the brainstem and modulate dorsal horn neurotransmission are deficient, with reduced serotonin and norepinephrine output. This dual dysfunction -- amplified excitatory input and diminished inhibitory control -- produces a state of generalized pain amplification. Functional magnetic resonance imaging studies demonstrate augmented pain responses in the insular cortex, anterior cingulate cortex, prefrontal cortex, and somatosensory cortex, confirming that fibromyalgia patients process painful stimuli differently at the cortical level. The concept of diffuse noxious inhibitory control, also termed conditioned pain modulation, is impaired in fibromyalgia, meaning that the normal phenomenon whereby one painful stimulus inhibits pain perception from another site is deficient, explaining the diffuse nature of pain amplification.

Neuroimaging Evidence

Advanced neuroimaging has provided compelling evidence for structural and functional brain changes in fibromyalgia. Functional MRI studies reveal increased connectivity between the default mode network and the insula, a pro-nociceptive pattern that distinguishes fibromyalgia patients from healthy controls. Volumetric analyses demonstrate reduced gray matter volume in pain-processing regions, suggesting that chronic pain may produce neurodegenerative changes. Positron emission tomography studies have shown elevated glutamate levels in the insular cortex and reduced mu-opioid receptor availability, the latter finding explaining why opioid medications are ineffective and may even worsen pain in this population. Magnetic resonance spectroscopy confirms that insular glutamate levels correlate directly with clinical pain severity, providing a potential biomarker for disease activity and treatment response.

Peripheral Contributions

Although fibromyalgia is fundamentally a disorder of central pain processing, peripheral contributions are increasingly recognized. Small fiber neuropathy, documented by reduced intraepidermal nerve fiber density on skin biopsy, is found in approximately 40 to 50 percent of fibromyalgia patients. This finding suggests that peripheral nociceptor sensitization may contribute to the maintenance of central sensitization through ongoing afferent input. Neurogenic inflammation, evidenced by elevated substance P and calcitonin gene-related peptide in peripheral tissues, provides another mechanism through which peripheral and central processes interact. Muscle abnormalities, including reduced capillarization and elevated lactate on MR spectroscopy, have been documented, though these are considered secondary to deconditioning and autonomic dysfunction rather than primary pathogenic features.

Neuroendocrine and Autonomic

Neuroendocrine dysregulation is a consistent finding in fibromyalgia. The hypothalamic-pituitary-adrenal axis demonstrates a blunted cortisol response to stress and disrupted diurnal cortisol rhythm. Autonomic dysfunction is manifested by reduced heart rate variability and sympathetic hyperactivity, which may contribute to fatigue, sleep disturbance, and cardiovascular symptoms. Growth hormone secretion is reduced in some patients, with low IGF-1 levels likely related to disrupted stage 3 and 4 sleep, during which growth hormone is primarily released. The characteristic sleep disturbance in fibromyalgia involves alpha-delta sleep intrusion, in which alpha waves intrude into delta (deep) sleep, producing non-restorative sleep that perpetuates the cycle of pain, fatigue, and cognitive dysfunction.

Risk Factors and Triggers

Genetic susceptibility plays a significant role in fibromyalgia, with familial aggregation demonstrating an eight-fold increased risk in first-degree relatives. Polymorphisms in genes involved in pain processing and neurotransmitter metabolism have been identified, including COMT (catechol-O-methyltransferase), SLC6A4 (serotonin transporter), HTR2A (serotonin receptor), and ADRB2 (beta-2 adrenergic receptor). Psychological factors including childhood adversity, post-traumatic stress disorder, anxiety, and depression have a bidirectional relationship with fibromyalgia, serving as both risk factors and consequences. Physical triggers such as trauma, surgery, infection (including post-COVID fibromyalgia), and whiplash injury can precipitate the onset of fibromyalgia in genetically susceptible individuals. The frequent co-occurrence of other central sensitivity syndromes, including irritable bowel syndrome, temporomandibular joint disorder, migraine, interstitial cystitis/painful bladder syndrome, and vulvodynia, suggests shared pathogenic mechanisms across these conditions.

<image>A neuroanatomy diagram illustrating central sensitization in fibromyalgia. Show a sagittal brain cross-section and spinal cord. In the spinal cord dorsal horn, depict an afferent C-fiber neuron synapsing with a second-order neuron, with elevated substance P and glutamate in the synaptic cleft. Show wind-up phenomenon with repeated stimulation leading to NMDA receptor activation and increased excitability. In the brainstem, show the descending pain modulation pathways (periaqueductal gray → rostral ventromedial medulla → dorsal horn) with reduced serotonin and norepinephrine output (shown as faded/reduced arrows). In the cortex, highlight the pain matrix areas (insular cortex, anterior cingulate, somatosensory cortex, prefrontal cortex) with exaggerated activation (shown as brighter/larger areas compared to normal). Include labels for all structures and neurotransmitters.</image>

Diagnosis

2016 ACR Revised Diagnostic Criteria

The 2016 ACR revised diagnostic criteria represent a significant advance over the 1990 criteria by eliminating the requirement for tender point examination, which was subjective and poorly reproducible. The current criteria require three conditions to be met. First, the patient must have a Widespread Pain Index of 7 or greater combined with a Symptom Severity Scale score of 5 or greater, or alternatively a WPI of 4 to 6 combined with an SSS score of 9 or greater. Second, generalized pain must be present, defined as pain in at least 4 of 5 body regions: left upper, right upper, left lower, right lower, and axial. Third, symptoms must have been present for at least 3 months. An important conceptual advance in the 2016 criteria is that the diagnosis of fibromyalgia is valid regardless of the presence of other diagnoses, formally recognizing that fibromyalgia can coexist with other conditions. The Widespread Pain Index counts the number of 19 specified body areas in which the patient has experienced pain during the past week, yielding a score of 0 to 19. The Symptom Severity Scale evaluates fatigue, waking unrefreshed, and cognitive symptoms, each scored 0 to 3 (yielding a subtotal of 0 to 9), plus the presence of headache, abdominal pain or cramping, and depression, each scored 0 or 1 (yielding a subtotal of 0 to 3), for a combined SSS range of 0 to 12.

Key Clinical Features (Beyond Pain)

The clinical picture of fibromyalgia extends well beyond widespread pain. Fatigue is pervasive and not relieved by rest, and for many patients it is more debilitating than the pain itself. Non-restorative sleep, characterized by waking unrefreshed despite adequate sleep duration, is a near-universal feature. Cognitive dysfunction, colloquially termed "fibro fog," manifests as impaired concentration, working memory deficits, and word-finding difficulty, and represents a real and measurable cognitive phenomenon on neuropsychological testing. Mood disturbance is common, with depression affecting 30 to 50 percent and anxiety affecting 30 to 60 percent of fibromyalgia patients. These are comorbid conditions with shared neurotransmitter pathways, not the cause of fibromyalgia. Functional somatic syndromes co-occur at high rates, including irritable bowel syndrome in 50 to 80 percent, migraine in 40 to 60 percent, temporomandibular joint disorder in 25 percent, and interstitial cystitis. Generalized sensory sensitivity, including photosensitivity, phonophobia, chemical sensitivity, and allodynia, reflects the broad central sensitization that characterizes the disorder.

Examination Findings

The physical examination in fibromyalgia is notable for the absence of objective musculoskeletal abnormalities. There is no synovitis, no true muscle weakness, and no joint deformity. Widespread tenderness to palpation is present, extending beyond the traditional tender point locations. The neurologic examination is normal. A useful clinical maneuver is control point tenderness testing, in which pain is elicited on palpation of areas not traditionally considered tender points, such as the forehead or thumbnail. Positive control point tenderness suggests central sensitization and supports the diagnosis of fibromyalgia.

Laboratory and Imaging

All routine laboratory tests are normal in fibromyalgia, including complete blood count, comprehensive metabolic panel, erythrocyte sedimentation rate, C-reactive protein, thyroid-stimulating hormone, antinuclear antibody, and rheumatoid factor. The purpose of laboratory testing is to exclude conditions that mimic fibromyalgia, not to diagnose it. A reasonable screening evaluation includes TSH to exclude hypothyroidism, 25-hydroxyvitamin D to assess for deficiency, inflammatory markers and autoantibodies (ESR, CRP, RF, anti-CCP) to evaluate for inflammatory arthritis, and polysomnography if sleep apnea is suspected. Imaging is not indicated for the diagnosis of fibromyalgia, though it may be necessary to evaluate coexistent conditions.

Differential Diagnosis

The differential diagnosis of fibromyalgia includes several conditions that can present with widespread pain and fatigue. Hypothyroidism should be excluded by checking TSH. Inflammatory arthritis, including rheumatoid arthritis, systemic lupus erythematosus, and spondyloarthritis, requires evaluation with inflammatory markers and autoantibodies. Polymyalgia rheumatica should be considered in patients over 50 with girdle pain and elevated ESR or CRP. Vitamin D deficiency can mimic fibromyalgia and should be assessed with a 25-hydroxyvitamin D level. Sleep disorders, particularly obstructive sleep apnea, may be investigated with polysomnography when clinical suspicion is present. Depression and anxiety should be screened for and treated independently, recognizing their comorbid rather than causative relationship with fibromyalgia. Drug-induced myalgia from statins or aromatase inhibitors should be considered based on medication history. Multiple sclerosis and myopathy enter the differential when neurologic findings are present on examination.

Management

Patient Education (ESSENTIAL FIRST STEP)

Patient education is the essential first step in fibromyalgia management and sets the foundation for all subsequent therapeutic interventions. The clinician should validate the diagnosis, clearly communicating that fibromyalgia is a real neurological condition involving abnormal pain processing in the central nervous system, not an imagined illness. Explaining central sensitization in understandable terms helps patients make sense of their symptoms and reduces the fear and frustration that frequently accompany this diagnosis. Realistic expectations should be set from the outset: the goal is meaningful improvement in symptoms and function rather than cure, and a multimodal approach combining multiple strategies is required for optimal outcomes. The patient's active role in management should be emphasized, as self-management strategies including exercise, sleep hygiene, and stress management are the most effective components of the treatment plan. Addressing catastrophizing and fear-avoidance beliefs is critical, as these cognitive patterns amplify pain perception and promote disability.

Non-Pharmacologic Therapies (FIRST-LINE)

Exercise

Exercise has the strongest evidence base of any fibromyalgia treatment and should be considered the cornerstone of management. Aerobic exercise, including walking, swimming, and cycling, has been strongly recommended by EULAR as the first-line intervention, with a number needed to treat of approximately 3 to 4 for meaningful improvement in pain and function. Strength training at moderate intensity also improves pain and function. Aquatic exercise is particularly effective due to the combination of warm water and reduced joint loading, making it an excellent option for patients who find land-based exercise difficult to tolerate. Complementary movement therapies including yoga and tai chi are supported by NCCIH-funded evidence, and the landmark study by Cheng and colleagues demonstrated that tai chi was non-inferior or superior to aerobic exercise for fibromyalgia outcomes. The critical principle for exercise prescription in fibromyalgia is to start low and progress gradually, avoiding post-exertional malaise while emphasizing consistency over intensity.

Cognitive Behavioral Therapy (CBT)

Cognitive behavioral therapy has strong evidence supporting its use in fibromyalgia pain management. CBT targets pain catastrophizing, provides sleep hygiene training, teaches activity pacing strategies, and develops stress management skills. Acceptance and commitment therapy is an emerging alternative that focuses on psychological flexibility and values-based action rather than symptom reduction. Online and application-based CBT programs offer an accessible option for patients who cannot attend in-person sessions, expanding the reach of this effective intervention.

Sleep Hygiene

Sleep hygiene is a critical component of fibromyalgia management because non-restorative sleep directly perpetuates central sensitization. Key recommendations include maintaining a consistent sleep schedule, creating a dark and cool sleeping environment, and limiting screen exposure before bedtime. Obstructive sleep apnea should be treated with continuous positive airway pressure if present, as this may improve fibromyalgia symptoms. Stimulants, alcohol, and heavy meals should be avoided before bed.

Pharmacologic Therapies

FDA-Approved Medications for FM

Three medications are currently FDA-approved for the treatment of fibromyalgia. Duloxetine, a serotonin-norepinephrine reuptake inhibitor, is dosed at 60 mg daily after titration from 30 mg. Its mechanism involves enhancement of descending serotonin and norepinephrine inhibitory pathways, and it also addresses comorbid depression and anxiety. Nausea is the most common side effect and is usually transient; other adverse effects include headache, dry mouth, and constipation. The number needed to treat for 30 percent pain reduction is approximately 8. Milnacipran, another SNRI with more norepinephrine-selective activity than duloxetine, is dosed at 50 mg twice daily after titration from 12.5 mg. Side effects include nausea, headache, constipation, hypertension, and tachycardia. Pregabalin, an alpha-2-delta ligand, is dosed at 150 to 225 mg twice daily for a total daily dose of 300 to 450 mg. Its mechanism involves reduction of excitatory neurotransmitter release, including glutamate and substance P, at the dorsal horn level, and it also improves sleep quality. Side effects include somnolence, dizziness, weight gain, peripheral edema, and cognitive effects. The number needed to treat for 30 percent pain reduction is approximately 12. Pregabalin is classified as a Schedule V controlled substance.

Other Commonly Used Medications

Several other medications are commonly used off-label for fibromyalgia. Gabapentin, dosed at 900 to 2400 mg daily in divided doses, has a similar mechanism to pregabalin and is frequently used as a lower-cost alternative. Amitriptyline, a tricyclic antidepressant dosed at 10 to 50 mg at bedtime, has the oldest evidence base for fibromyalgia treatment and improves pain, sleep, and fatigue, with a number needed to treat of approximately 4 for moderate pain improvement based on Cochrane data. Its anticholinergic side effects, including dry mouth, constipation, urinary retention, sedation, and weight gain, limit its use in some patients. Cyclobenzaprine, dosed at 5 to 10 mg at bedtime and structurally similar to amitriptyline, primarily improves sleep quality. Low-dose naltrexone at 1.5 to 4.5 mg daily is an emerging option with an anti-microglial mechanism, supported by evidence from small trials and notable for its favorable tolerability profile. Memantine, an NMDA receptor antagonist, has limited evidence and is under investigation.

Medications to AVOID in FM

Several medication classes should be specifically avoided in fibromyalgia. Opioids are strongly recommended against because they worsen central sensitization through opioid-induced hyperalgesia, have no evidence of efficacy for fibromyalgia pain, and carry a high risk of dependency. Benzodiazepines worsen sleep architecture and carry dependency risk. Non-steroidal anti-inflammatory drugs are ineffective for fibromyalgia because there is no peripheral inflammation to target; the pain is centrally generated. Glucocorticoids provide no benefit and carry significant side effects.

<image>A multimodal management plan diagram for fibromyalgia, organized as a wheel with the patient at center and treatment modalities as spokes. Inner ring (first-line, strongest evidence): Exercise (aerobic + strengthening), patient education, CBT, sleep hygiene. Middle ring (pharmacologic): Duloxetine/milnacipran (SNRIs), pregabalin/gabapentin (alpha-2-delta ligands), amitriptyline (TCA at low dose). Outer ring (adjunctive): Acupuncture, aquatic therapy, yoga/tai chi, LDN. Outside the wheel, show interventions NOT recommended with red X marks: opioids, benzodiazepines, NSAIDs, corticosteroids. Include a note that the best outcomes combine non-pharmacologic and pharmacologic approaches. Use color coding: green for strong evidence, yellow for moderate evidence, red for not recommended.</image>

FM and Coexistent Rheumatic Disease

Fibromyalgia frequently coexists with other rheumatic conditions, affecting 15 to 25 percent of rheumatoid arthritis patients, 20 to 30 percent of systemic lupus erythematosus patients, 10 to 20 percent of spondyloarthritis patients, and 20 to 30 percent of osteoarthritis patients. This coexistence creates a critical clinical challenge: distinguishing fibromyalgia symptoms from active inflammatory disease. Fibromyalgia does not cause elevated ESR or CRP, synovitis on examination, or joint damage on imaging. When patient global assessment scores and pain visual analog scores remain high despite adequate control of inflammatory markers and objective disease measures, the clinician should suspect a fibromyalgia component. The most significant risk of unrecognized concomitant fibromyalgia is overtreatment, in which immunosuppressive therapy is inappropriately escalated for symptoms that are driven by central sensitization rather than inflammatory disease activity. The solution is to use objective measures -- including joint counts, imaging, and acute phase reactants -- to assess inflammatory disease activity separately from fibromyalgia-related symptoms, and to treat each condition with its appropriate therapeutic strategy.

Key Clinical Pearls

• FM is NOT a diagnosis of exclusion; it can be positively diagnosed using 2016 ACR criteria and can coexist with other diseases
• Exercise is the most effective treatment for FM (NNT 3-4); must be started low and progressed gradually
• Opioids are contraindicated in FM: They worsen central sensitization and have no evidence of benefit
• NSAIDs are ineffective for FM because there is no peripheral inflammation to target
• FM coexisting with RA or SLE can lead to overtreatment of the inflammatory disease; use objective markers to guide immunosuppression decisions
• "Fibro fog" is a real cognitive phenomenon; patients have measurable deficits in working memory and attention

References

1. Wolfe F, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319-329.
2. Macfarlane GJ, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328.
3. Clauw DJ. Fibromyalgia: a clinical review. JAMA. 2014;311(15):1547-1555.
4. Wang C, et al. Effect of tai chi versus aerobic exercise for fibromyalgia (comparison study). BMJ. 2018;360:k851.
5. Harte SE, et al. The neurobiology of central sensitization. J Appl Biobehav Res. 2018;23(1):e12137.

Read this lecture as Markdown